share_log

Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years Older.

Benzinga ·  Sep 17 12:08
Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years Older.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment